Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Saskatoon Paramedic Association votes 100% in favour of strike mandate

February 4, 2026

Kelowna residents warned to stay alert following theft of paramedic uniform

February 4, 2026

Google’s Pixel 10A will be revealed on February 18th

February 4, 2026

Acronis Welcomes Insightz Technology as First MSSP Partner in Singapore

February 4, 2026

Calgarians concerned over permit approvals ahead of citywide rezoning debate

February 4, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030
Press Release

Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030

By News RoomJanuary 15, 20263 Mins Read
Genetic Modification Therapies Set to Surge, Market Valued at .1 Billion by 2030
Share
Facebook Twitter LinkedIn Pinterest Email
Genetic Modification Therapies Set to Surge, Market Valued at .1 Billion by 2030

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) — The “Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing” has been added to ResearchAndMarkets.com’s offering.

The global market for genetic modification therapies is projected to expand from $14.8 billion in 2025 to $32.1 billion by 2030, boasting a compound annual growth rate (CAGR) of 16.8% within this period.

Genetic modification therapies represent cutting-edge biologic interventions developed by altering genetic material. The promising platforms in this sector, including gene therapy and RNA therapy, are poised to transform treatment for conditions that currently have limited therapeutic options. These specialized therapies, often designed as one-time interventions for rare genetic disorders, hold immense potential as their clinical pipeline strengthens, attracting numerous biopharmaceutical entities. Currently, these therapies are applicable to rare diseases, cancer, and hematological issues, with future approvals anticipated in areas such as musculoskeletal, cardiovascular, and neurological conditions.

The report offers a comprehensive analysis of genetic modification therapies, including clinical applications such as gene therapies, genetically modified cell therapies, RNA therapies, and the gene editing market. It examines global market trends, providing revenue data for 2024, projected estimates for 2025, and forecasts extending to 2030. The market is dissected by platform technology, application, and region.

Segmentation by platform technology includes gene editing, gene therapy, gene-modified cell therapy, and RNA therapy. Application segments cover oncology, rare diseases, cardiovascular and musculoskeletal conditions, and hematological disorders. The gene therapy sector is further categorized by delivery systems such as adeno-associated virus (AAV), herpes simplex virus-1, and lentivirus. RNA therapies are divided into antisense oligonucleotides and small interfering RNAs, among others.

The report includes:

  • 103 data tables and 63 additional tables
  • Insights and analysis of the global genetic modification therapies market
  • Thorough market trend analysis, displaying historical revenue (2022-2024), estimates for 2025, and forecasts until 2030, including CAGR projections
  • Current market size evaluation and future revenue growth prospects, with market share analysis by platform technology, application, and region
  • Demand dynamics and detailed competitive environment analysis, along with market regulations and reimbursement practices
  • Gene editing, gene therapy, CAR T-cell therapy, RNA therapy, and lentiviral production roles in the therapeutic landscape
  • Drivers, challenges, and opportunities influencing market growth
  • Technological advancements, future market potential, R&D activities, growth strategies, new product pipelines, and ESG trends
  • Market share analysis of industry leaders, focusing on research priorities, product portfolios, global rankings, and competitive landscapes
  • Profiles of leading companies: Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Novartis AG, Bristol-Myers Squibb Co., and Sarepta Therapeutics Inc.

Key Attributes:

Report Attribute Details
No. of Pages 166
Forecast Period 2025 – 2030
Estimated Market Value (USD) in 2025 $14.8 Billion
Forecasted Market Value (USD) by 2030 $32.1 Billion
Compound Annual Growth Rate 16.8%
Regions Covered Global

Companies Featured

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Ferring Pharmaceuticals
  • Genetix Biotherapeutics Inc.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Lilly USA LLC
  • Novartis AG
  • Novo Nordisk A/S
  • Sanofi
  • Sarepta Therapeutics Inc.
  • Vertex Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/vjfgoj

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Genetic Modification Therapies Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Acronis Welcomes Insightz Technology as First MSSP Partner in Singapore

Data Center Migration Global Market Report 2025: $26.77 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F

Nasdaq Renews Notified as Exclusive IR Communications Technology Partner for New Listings

HondaJet Elite II Certified by FAA to Become First Production Model Twin-Turbine Very Light Business Jet Available with Emergency Autoland

Komodor Named a Representative Vendor in the 2026 Gartner® Market Guide for AI Site Reliability Engineering Tooling

Digital Badge Access Control for Data Centers (DCs) Global Market Report 2025: $4.71 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F

PerfectServe is Again Best in KLAS for Physician Scheduling and Ambulatory Clinical Communications

Edge Print Servers for Data Centers (DCs) Global Market Report 2025: $4.28 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F

Data Center UPS Market Report 2026: $7.75+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Editors Picks

Kelowna residents warned to stay alert following theft of paramedic uniform

February 4, 2026

Google’s Pixel 10A will be revealed on February 18th

February 4, 2026

Acronis Welcomes Insightz Technology as First MSSP Partner in Singapore

February 4, 2026

Calgarians concerned over permit approvals ahead of citywide rezoning debate

February 4, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Fundraisers start for hockey families after crash

February 4, 2026

Valve’s Steam Machine has been delayed, and the RAM crisis will impact pricing

February 4, 2026

Data Center Migration Global Market Report 2025: $26.77 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F

February 4, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version